Description
IrsoglADIneexhibitsanti-inflammatory,anti-fibrotic,andmucoprotectiveactivities.Irsogladinedecreasesnon-steroidalanti-inflammatorydrug(NSAID)-inducedintestinalmucosalinjury,ulcers,andesophagitis;itinhibitsCOX-1andCOX-2.Inanimalmodelsofcolitis,irsogladinepreventsDDS-inducedincreasesinTGF-β1,collagentype1,MMP2,TIMP-1,andα-SMA,preventingfibrosis.Additionally,irsogladinenon-selectivelyinhibitsphosphodiesterases,increasingcAMPandNO,facilitatinggapjunctioncommunicationandalteringgastricmucosalbloodflow.
References
KuramotoT,UmegakiE,NoudaS,etal.Preventiveeffectofirsogladineoromeprazoleonnon-steroidalanti-inflammatorydrug-inducedesophagitis,pepticulcers,andsmallintestinallesionsinhumans,aProspectiverandomizedcontrolledstudy.BMCGastroenterol.2013May14;13:85.PMID:23672202.
AkagiM,AmagaseK,MurakamiT,etal.Irsogladine:overviewofthemechanismsofmucosalprotectiveandhealing-promotingactionsinthegastrointestinaltract.CurrPharmDes.2013;19(1):106-14.PMID:22950502.
YamaguchiH,SuzukiK,NagataM,etal.Irsogladinemaleateamelioratesinflammationandfibrosisinmicewithchroniccolitisinducedbydextransulfatesodium.MedMolMorphol.2012Jun;45(3):140-51.PMID:23001296.